7 Posts Not to Miss From the EHA 2025 – Nico Gagelmann
The European Hematology Association (EHA) 2025 events bring together global experts to explore the latest advances in hematology. This year features two major gatherings: the EHA Research Conference (March 17–20 in Málaga, Spain), focusing on transcriptional control and chromatin in hematopoiesis, and the 30th EHA Annual Congress (June 12–15 in Milan, Italy), a hybrid event showcasing cutting-edge research, clinical updates, and educational sessions.
EHA 2025 offers a unique platform for knowledge exchange, collaboration, and innovation in blood disorders and research.
Nico Gagelmann, Young National Society Ambassador at European Hematology Association (EHA) and Chair of the CAR-T for plasma cell disorder committee at The EBMT, shared following posts from EHA 2025 on X:
1. “The best way to learn is from and with different generations.”
2. “Friends make medicine, science and life better, better together”
3. “Amazing session at EHA2025 with Coleman Lindsley and Mike Spencer Chapman chaired by Anna Sureda on
– Donor selection in families with recurreny myeloid mutations / Donor clonal hematopoiesis and recipient outcomes after transplantation
– Philogenetics of donor derived hematopoiesis”
4. “Fresh start with Clonal Hematopoiesis at last day of EHA2025 with Mikko Myllymäki”
5. “Excellent presentation by Carmelo Gurnari on the clinico genomic features of therapy-related myeloid neoplasm in EHA2025.”
6. “Fascinating European Hematology Association and The EBMT session at EHA2025 chaired by
Anna Sureda and Konstanze Döhner covering
New strategies for mismatched SCT (advances in donor selection and immunosuppression) by F Ciceri
The role of CAR-T as bridging to SCT (CAR-T vs SCT, or CAR-T and SCT?) by MariSubklewe
Outpatient CAR-T by Alexandra Martínez-Roca”
7. “Amazing Young EHA session at EHA2025 on critical appraisal of trialsSurrogates by Come Bommier.
Trial interpretation Eddie Cliff
And much more giving food for brain.”
Find more posts featuring EHA 2025 on Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025